CCL4 as a potential serum factor in differential diagnosis of central nervous system inflammatory diseases and gliomas

Tian‐Jie Lyu, Jia Wang, Fengmao Zhao, Ke Sun, Zheng Zhao, Runfa Tian, Zhendong Guo, Haoran Wang, Xin Zhao, Wenping Ma, Mingshan Zhang, Wangshu XuFrontiers in Immunology 2024 · DOI

TL;DR

Researchers have identified the chemokine CCL4 as a highly effective serum biomarker for distinguishing between brain gliomas and central nervous system (CNS) inflammatory diseases. This discovery offers a potential non-invasive diagnostic tool that could reduce the reliance on risky brain biopsies when medical imaging proves inconclusive.

What Problem Does This Paper Address?

In neurology, "the great mimics" are a constant challenge. Brain gliomas (malignant tumors) and CNS inflammatory diseases (like multiple sclerosis or encephalitis) often appear nearly identical on standard CT and MRI scans. However, their treatments are diametrically opposed: one requires aggressive surgery and chemotherapy, while the other typically requires immunosuppressants or steroids.

Currently, the only "gold standard" for a definitive diagnosis is a pathological analysis of brain tissue. This requires a craniotomy or stereotaxic biopsy—invasive procedures that carry significant risks, including cerebral hemorrhage, neurological deficits, and infection. There is a critical need for a "liquid biopsy"—a blood or cerebrospinal fluid (CSF) test—that can accurately differentiate these conditions without opening the skull.

Methods

The researchers employed a multi-stage approach to find a reliable biomarker:

  1. Cytokine Screening: They initially analyzed paired serum and CSF samples from a small cohort (4 glioma patients, 5 inflammation patients) using the ABplex 40-Plex Assay. This allowed them to simultaneously quantify 40 different human cytokines, chemokines, and growth factors.
  2. Statistical Filtering: They used Receiver Operating Characteristic (ROC) analysis to evaluate the sensitivity and specificity of these factors. Crucially, they also performed Pearson correlation analysis to see which factors in the blood (serum) most accurately reflected the environment in the brain fluid (CSF).
  3. Validation: The most promising candidate, CCL4, was then validated in a larger clinical cohort (19 glioma patients, 22 inflammation patients) using ELISA (Enzyme-Linked Immunosorbent Assay), a standard laboratory technique for protein quantification.

Datasets

The study utilized clinical samples collected from Beijing Tiantan Hospital and Beijing Children’s Hospital:

  • Screening Set: 9 patients (4 glioma, 5 CNS inflammation) plus 8 control patients with cranial hypertension.
  • Validation Set: 41 patients (19 glioma, 22 CNS inflammation).
  • Sample Types: Matched serum and cerebrospinal fluid (CSF).

Key Insights and Ideas

  • The Serum-CSF Bridge: One of the most significant findings was the strong correlation (r = 0.92) between CCL4 levels in the serum and the CSF. This suggests that CCL4 effectively crosses or reflects the state of the blood-brain barrier, making a simple blood test a viable proxy for what is happening inside the CNS.
  • Inflammatory "Noise": While 10 different factors (including IL-4, IFN-γ, and VEGF) were significantly higher in the inflammation group, CCL4 provided the cleanest statistical separation.
  • CCL4's Biological Role: Also known as Macrophage Inflammatory Protein-1 beta (MIP-1β), CCL4 is a chemokine that recruits immune cells. The study highlights that while CCL4 is involved in tumor progression, its levels are markedly higher in acute inflammatory states compared to the immunosuppressive environment often created by gliomas.

Key Results

  • Top Candidates: Ten factors showed significant differences in serum levels (p < 0.05), but CCL4 was the standout performer.
  • Diagnostic Accuracy: In the validation cohort, serum CCL4 levels were significantly higher in the inflammatory group compared to the glioma group (p < 0.001).
  • ROC Performance: The ROC analysis for CCL4 yielded an AUC (Area Under the Curve) of 0.8182, with a suggested diagnostic cutoff value of 969.6 pg/ml.
  • Correlation: The correlation coefficient for CCL4 between serum and CSF was 0.92 (95% CI = 0.20–0.99, p = 0.027), the highest among the factors tested.

Limitations and Future Work

While promising, the authors acknowledge several hurdles before this can reach the clinic:

  • Sample Size: The study is relatively small (n=41 for validation). Larger, multi-center studies are needed to confirm the diagnostic cutoff across diverse populations.
  • Confounding Factors: The research did not fully account for patient comorbidities, specific medication use (like prior steroid treatment), or other neurological conditions that might influence cytokine levels.
  • Mechanistic Depth: While the correlation is clear, the exact molecular mechanisms driving the differential expression of CCL4 in these specific disease states require further investigation.
  • Control Groups: Future work should include a wider variety of "control" diseases to ensure CCL4 is specific to this differential diagnosis and not just a general marker of any neurological distress.

Summary updated

Abstract

Computed tomography (CT) scans and magnetic resonance imaging (MRI) are commonly utilized to detect brain gliomas and central nervous system inflammation diseases. However, there are instances where depending solely on medical imaging for a precise diagnosis may result in unsuitable medications or treatments. Pathological analysis is regarded as the definitive method for diagnosing brain gliomas or central nervous system inflammation diseases. To achieve this, a craniotomy or stereotaxic biopsy is necessary to collect brain tissue, which can lead to complications such as cerebral hemorrhage, neurological deficits, cerebrospinal fluid leaks, and cerebral edema. Consequently, the advancement of non-invasive or minimally invasive diagnostic techniques is currently a high priority. This study included samples from four glioma patients and five patients with central nervous system inflammatory diseases, comprising both serum and paired cerebrospinal fluid (CSF). A total of 40 human cytokines were identified in these samples. We utilized a receiver operating characteristic (ROC) analysis to assess the sensitivity and specificity for distinguishing central nervous system inflammation diseases and gliomas. Additionally, we examined the correlation of these factors between serum and CSF in the patients. Ultimately, the identified factors were validated using serum from patients with clinically confirmed gliomas and central nervous system inflammation diseases followed by detection and statistical analysis through ELISA. The levels of serum factors IL-4, IFN-α, IFN-γ, IL-6, TNF-α, CCL4, CCL11, and VEGF were found to be significantly higher in gliomas compared with inflammatory diseases of the central nervous system (p < 0.05). Furthermore, a strong correlation was observed between the levels of CCL4 in serum and CSF, with a correlation coefficient of r = 0.92 (95% CI = 0.20-0.99, p = 0.027). We gathered more clinical samples to provide further validation of the abundance of CCL4 expression. A clinical study analyzing serum samples from 19 glioma patients and 22 patients with central nervous system inflammation diseases revealed that CCL4 levels were notably elevated in the inflammatory group compared with the glioma group (p < 0.001). These results suggest that assessing serum CCL4 levels may be useful in distinguishing those patients for clinical diagnostic purposes.
BibTeX
@inproceedings{lyu2024ccl,
  author = {Tian‐Jie Lyu and Jia Wang and Fengmao Zhao and Ke Sun and Zheng Zhao and Runfa Tian and Zhendong Guo and Haoran Wang and Xin Zhao and Wenping Ma and Mingshan Zhang and Wangshu Xu},
  title = {{CCL4 as a potential serum factor in differential diagnosis of central nervous system inflammatory diseases and gliomas}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1461450},
}
Figure